Treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The study is ongoing and further data will be required to determine long-term outcome.
\nTreatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
\nClinical benefit, such as improvement in disease-related symptoms or increased survival, has not been demonstrated.<\/p>\n
Tasigna (nilotinib Capsules) for oral use Initial U.S. Approval: 2007
\nTo access nilotinib Capsules sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Tasigna (nilotinib) is a prescription medicine used to treat chronic myelogenous leukaemia (CML) in patients who have the Philadelphia chromosome. It may be used in people who have been newly diagnosed or who cannot take other cancer medicines (including imatinib).<\/p>\n
Disease Indications-Leukemia If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cNilotinib Capsules\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Novartis
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), \u00a0Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n